InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
4
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
+7.0%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Culley Brian M, Président et CEO. Officer active across 1 company, notably Lineage Cell Therapeutics, Inc.. Cumulatively, 14 reports have been published. Split: 4 buys · 0 sell. Total volume traded: €60k. History available since 28 June 2021. The latest transaction was disclosed on 12 March 2026 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Culley Brian M
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations14 total
15,000 shares@ US$1.6259.0% of flowCommon SharesSEC:0001193125-26-104106:0
Canonical exit: 10 Jun 2026 (T+90)
31,250 sharesCommon SharesSEC:0001193125-26-052021:0
8,925 sharesCommon SharesSEC:0001193125-25-327280:0
31,249 sharesCommon SharesSEC:0000950170-25-018887:0
40,000 shares@ US$0.605.9% of flowCommon SharesSEC:0000950170-24-129972:0
Canonical exit: 19 Feb 2025 (T+90)
10,000 shares@ US$1.052.5% of flowCommon SharesSEC:0000950170-24-064896:0
Canonical exit: 22 Aug 2024 (T+90)
31,249 sharesCommon Shares, no par valueSEC:0001493152-24-005942:0
31,249 sharesCommon Shares, no par valueSEC:0001493152-23-004898:0
15,450 sharesCommon Shares, no par valueSEC:0001493152-22-018271:0
15,450 sharesCommon Shares, no par valueSEC:0001493152-22-009000:0
5,250 shares@ US$1.382.8% of flowCommon Shares, no par valueSEC:0001493152-22-007925:0
Canonical exit: 23 Jun 2022 (T+90)
15,450 sharesCommon Shares, no par valueSEC:0001493152-22-000116:0
15,450 sharesCommon Shares, no par valueSEC:0001493152-21-025197:0
300,000 shares@ US$0.691974.3% of flowCommon Shares, no par valueSEC:0001493152-21-015778:0
14 of 14 declarations
About Culley Brian M
Culley Brian M is President and CEO of Lineage Cell Therapeutics, Inc. He has 14 filings in total, and across the sampled recent filings, buy volume is EUR 60165 and sell volume is EUR 0, from 2021-06-30 to 2026-03-12, with Levée d'options as the most frequent transaction type.
